Site Map

Home
Why ITVISMA
- ITVISMA Results
- How ITVISMA Works
- Understanding Safety
Path to ITVISMA
Support
- Novartis Patient Support™
- Connecting With the SMA Community
Resources
- Downloadable Resources
- Frequently Asked Questions
- Sign Up for Support
Dosing
Share Your Story

IMPORTANT SAFETY INFORMATION

What is the most important safety information I should know about ITVISMA?

ITVISMA can increase liver enzyme levels and cause hepatotoxicity.
Patients will receive an oral corticosteroid medication before and after ITVISMA injection and will undergo regular blood tests to monitor liver function.
Patients and caregivers should contact the patient’s doctor immediately if the patient’s skin and/or whites of the eyes become yellowish, if the patient misses a dose of corticosteroid or vomits it up, or if the patient experiences a decrease in alertness.

INDICATION

What is ITVISMA?

ITVISMA is a prescription gene therapy used to treat adults and children 2 years of age and older with spinal muscular atrophy (SMA). ITVISMA is given as a one-time intrathecal injection.

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION